Data Insights

By Company Name

By Disease Name

By Drug Name

By Themes

Showing 5 results out of 5

Data Insights

Blarcamesine hydrochloride by Anavex Life Sciences for Fragile X Syndrome: Likelihood of Approval

Blarcamesine hydrochloride is under clinical development by Anavex Life Sciences and currently in Phase I for Fragile X Syndrome. According...

Likelihood of Approval and Phase Transition Success Rate Model - Blarcamesine Hydrochloride in Fragile X Syndrome

Data Insights

ANAVEX-371 by Anavex Life Sciences for Schizophrenia: Likelihood of Approval

ANAVEX-371 is under clinical development by Anavex Life Sciences and currently in Phase II for Schizophrenia. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - ANAVEX-371 in Schizophrenia

Data Insights

Blarcamesine hydrochloride by Anavex Life Sciences for Infantile Spasm (West Syndrome): Likelihood of Approval

Blarcamesine hydrochloride is under clinical development by Anavex Life Sciences and currently in Phase I for Infantile Spasm (West Syndrome)....

Likelihood of Approval and Phase Transition Success Rate Model - Blarcamesine Hydrochloride in Infantile Spasm (West Syndrome)

Data Insights

ANAVEX-371 by Anavex Life Sciences for Frontotemporal Dementia (FTD): Likelihood of Approval

ANAVEX-371 is under clinical development by Anavex Life Sciences and currently in Phase I for Frontotemporal Dementia (FTD). According to...

Data Insights

Blarcamesine hydrochloride by Anavex Life Sciences for Angelman Syndrome: Likelihood of Approval

Blarcamesine hydrochloride is under clinical development by Anavex Life Sciences and currently in Phase I for Angelman Syndrome. According to...